Pre-Ozempic Obesity Drugs


About Older Obesity Meds
Before the rise of popular GLP-1 medications like Ozempic, Wegovy, and Zepbound, there were other effective and budget-friendly weight loss drugs. These medications, such as naltrexone/bupropion extended release (Contrave), orlistat (Xenical), and phentermine/topiramate (Qsymia), have been around for decades and offer a valuable alternative.

Orlistat (Xenical)
Orlistat, marketed under the brand name Xenical, inhibits the absorption of fats, thus reducing calorie intake. This medication has been around for a long time and is known for its safety and effectiveness. Users typically experience weight loss of around 5% to 6% of their total body weight. One notable advantage of Xenical is its cost, which ranges from $200 to $300 per month, significantly less than GLP-1 medications.

Phentermine
Phentermine, one of the oldest obesity medications, datesback to the 1950s and 1960s. Despite its age, it remains widely prescribed due to its effectiveness and affordability. Phentermine works as an appetite suppressant, helping users reduce their calorie intake. Its cost is a major benefit, with generic versions available for as low as $20 per month, making it an accessible option for many.

Phentermine/Topiramate (Qsymia)
This combination extended-release formula suppresses appetite. This dual mechanism helps reduce hunger and prolongs the feeling of fullness, which can decrease overall calorie intake. Studies have shown that Qsymia can lead to a weight loss of up to 13% of total body weight at higher doses. And it is cost-effective, with some patients paying just $100 per month with drugmaker coupons.

Naltrexone/Bupropion Extended Release (Contrave)
Contrave is a combination therapy that targets the brain’s hunger and reward centers. This medication helps manage cravings and reduce food intake, resulting in an average weight loss of about 9%. Contrave is another budget-friendly option, with costs as low as $100 per month with coupons.

Oral vs. Injection
One of the key differences between older obesity medications and newer GLP-1 drugs is how you tske it. Most older drugs are taken orally, providing a convenient and noninvasive option. GLP-1 medications are injections, which can be a barrier for some patients.

Side Effects
Older obesity medications tend to avoid many of the gastrointestinal side effects commonly associated with GLP-1 drugs. Medications like Contrave, phentermine, and Qsymia do not typically cause nausea, vomiting, and gastroparesis (stomach paralysis) often reported with GLP-1s. This can make the older drugs more tolerable and appealing to many patients.

Cost Comparison
Newer GLP-1 drugs like Ozempic and Wegovy are known for their impressive weight loss results, often reaching double digits. However, these medications come with a hefty price tag, ranging from $500 to thousands of dollars per month. In contrast, older medications offer a more economical solution without compromising effectiveness.

Individualized Treatment Plans
Obesity medicine is not a one-size-fits-all solution. Different medications work for different people based on their unique physiological responses, eating habits, and lifestyles. While newer drugs may be popular, older medications should not be overlooked. Consulting with a health care provider can help determine the best treatment plan tailored to an individual's needs.
Photo Credits:
Slide 1: Moment/Getty Images
Slide 2: E+/Getty Images
Slide 3: The Image Bank/Getty IMges
Slide 4: E+/Getty Images
Slide 5: Rawpixel.com/Shutterstock
Slide 6: Brian Chase/Shutterstock
Slide 7: E+/Getty Images
Slide 8: Gopixa/Dreamstime
Slide 9: iStock/Getty Images Plus
Anthony Auriemma, MD, medical director, Ascension Illinois Weight Loss Solutions.
Andres Acosta, MD, obesity expert, Mayo Clinic.
John Amos, CEO, VIVUS LLC.
News release, Institute for Clinical and Economic Review.
ESHA Research Inc., Salem, OR.
European Journal of Endocrinology: “A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome.”
Evidence-Based Complementary Alternative Medicine: “Berberine Improves Insulin Sensitivity by Inhibiting Fat Store and Adjusting Adipokines Profile in Human Preadipocytes and Metabolic Syndrome Patients.”
Frontiers in Pharmacology: “Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders.”
High Blood Pressure and Cardiovascular Prevention: “Nutraceuticals for blood pressure control in patients with high-normal or grade 1 hypertension.”
Journal of Ethnopharmacology: “Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipidemia and hypertension.”
Metabolism: Clinical and Experimental: “Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.”
Nature Medicine: “Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.”
Phytomedicine: “Lipid-lowering effect of berberine in human subjects and rats.”
Science China Life Sciences: “Learning from berberine: Treating chronic diseases through multiple targets.”
Acta Pharmaceutica Sinica B: “Berberine ameliorates chronic kidney disease through inhibiting the production of gut-derived uremic toxins in the gut microbiota.”
Poison Control: “What are the benefits of berberine?”
National Library of Medicine: “Berberine.”
FDA: "Beware of Fraudulent Weight-Loss Dietary Supplements," "Tainted Weight Loss Products," "Weight Loss Fraud: Know What You're Taking," "Questions and Answers about FDA's Initiative Against Contaminated Weight Loss Products."
Natural Medicines Comprehensive Database: "Natural Medicines in the Clinical Management of Obesity," "7-Keto-DHEA," "Hoodia," "Guar Gum," "Green Coffee Extract," "Green Tea Extract," "Glucomannan," "Conjugated Linoleic Acid," "Chromium," "Chitosan."
National Center for Complementary and Alternative Medicine: "Bitter Orange," "Ephedra," "Hoodia," "Effects of Chromium Picolinate in People at Risk for Type 2 Diabetes," "Green Tea."
National Institutes of Health Office of Dietary Supplements: "Chromium."
National Library of Medicine: "Senna."
Micronutrient Information Center, Linus Pauling Institute, Oregon State University.
University of Maryland Medical Center: "Ephedra."
Hydroxycut website.
Said, O. The Open Complementary Medicine Journal, 2010.
FDA: "Questions and Answers: Hydroxycut," "Warning on Hydroxycut Products," "Beware of Fraudulent Weight-Loss 'Dietary Supplements.'"
Antaki Center for Herbal Medicine.
Phytotherapie, November 2006.
John Doherty, director of regulatory affairs, Iovate Health Sciences International.
Vinson, J. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2012.
Watanabe, T. Clinical and Experimental Hypertension, July 2006.